ADHFE1 and glioblastoma: Our additional methylation analysis using the Wanderer database further strengthens the diagnostic potential of hypermethylated ADHFE1 in detecting CRC as we observed that the methylation of ADHFE1 displayed significant differences in CRCs versus normal tissues as compared to other cancers, for instance, glioblastoma multiforme (GBM), breast-invasive carcinoma, esophageal carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma, prostate adenocarcinoma, and thyroid carcinoma.